FindTrial
Sign In

Role of Aparajit Avaleha in treatment of Dry Cough

A clinical study to evaluate the efficacy of Aparajit Avaleha in the management of Vataja Kasa in children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/12/022302
Enrollment
30
Registered
2019-12-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J069- Acute upper respiratory infection,unspecified

Interventions

Intervention1: Aparajit Avaleha: Aparajit Avaleha DOSE (6-9 years) 20gm divided in three dose after food for 14 days. DOSE (9-12 years) 30gm divided in three dose after food for 14 days Route of Admi

Sponsors

Department of Kaumarbhritya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of Vataja Kasa with symptoms Parshavshool, Shirashool, Urashool, Sawarbheda, Shuska Mukha and Gala as a major symptoms. 2.Acute Cough of less than 7 days. 3.Newly diagnosed cases of Vataja Kasa.

Exclusion criteria

Exclusion criteria: 1.Patients below age of 6 years and above age of 12 years. 2.Patients with chronic debilitating disease or disorders. 3.All types of Kasa except Vataja Kasa Lakshana will be excluded. 4.Conditions like Pneumonia, Juvenile Diabetes Mellitus, Tuberculosis, Bronchiolitis, Asthma Cough with High Grade Fever. 5.If Cough aggravates during treatment then it will be excluded.

Design outcomes

Primary

MeasureTime frame
A beneficial effect of Aparajit Avaleha in the management of Vataja Kasa in childrenTimepoint: 21 Days—

Secondary

MeasureTime frame
To study the mode of action of Aparajita Avaleha in management of Vataja KasaTimepoint: 21 Days—

Countries

India

Contacts

Public ContactDr Aboli Patil

Parul Institute of Ayurved

drabolipatil@gmail.com7498549893

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026